Granted Patent
B2
US 12,458,654 · App. 17/954,070 · Granted Nov 4, 2025
Methods of conditioning patients for T cell therapy
Inventors:
Adrian Bot (Santa Monica, CA); Jeffrey Wiezorek (Santa Monica, CA); William Go (Santa Monica, CA); Rajul Jain (Santa Monica, CA); James N. Kochenderfer (Bethesda, MD); Steven A. Rosenberg (Bethesda, MD)
Assignees:
Kite Pharma Inc.; United States of America, as represented by the Secretary, Department of Health and Human Services
A61K31/664A61K31/675A61K31/7076A61K38/2013A61K38/2053A61K40/11A61K40/31A61K40/4211A61K45/06A61P35/02A61K2239/31A61K2239/38A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
Claims (12)
1 . A method of treating a patient having a tumor comprising (i) administering to the patient a single dose of cyclophosphamide at about 900 mg/m 2 /day and one or more doses of fludarabine at about 25 mg/m 2 /day; and (ii) administering to the patient a therapeutically effective amount of engineered chimeric antigen receptor (CAR) T cells, wherein the patient is determined to have an increase in the serum levels of IL-15 of at least 5-fold, IL-7 of at least 2-fold, and an increase in at least one of MCP-1 or CRP of at least 1.5 fold or IP-10 of at least 2-fold on the day of but prior to administration of the CAR-T cells, after the administration of cyclophosphamide and fludarabine; wherein the tumor is a leukemia and the engineered CAR-T cells are anti-CD19 CAR-T cells.
2 . The method of claim 1 , wherein the administration of cyclophosphamide and fludarabine (i) reduces endogenous lymphocytes, (ii) increases a serum level of a homeostatic cytokine, (iii) enhances an effector function of T cells administered after the conditioning, (iv) enhances antigen presenting cell activation and/or availability, or (v) any combination thereof.
3 . The method of claim 1 , wherein each dose of fludarabine is administered daily for three days.
4 . The method of claim 1 , wherein each dose of cyclophosphamide is administered before, after, or concurrently with the dose of fludarabine.
5 . The method of claim 4 , wherein the dose of cyclophosphamide is administered before the dose of fludarabine.
6 . The method of claim 1 , wherein the cyclophosphamide is administered once on day −2 and/or the fludarabine is administered on days −4, −3, and −2.
7 . The method of claim 1 , wherein the administration of cyclophosphamide and fludarabine induces an improved antitumor efficacy of the CAR-T cell administration compared to the antitumor efficacy of the CAR-T cell administration without the administration of cyclophosphamide and fludarabine.
8 . The method of 1 , wherein the patient after the administration of cyclophosphamide and fludarabine and/or the T cell therapy further exhibits an increased serum concentration of a cytokine or a pro-inflammatory factor selected from the group consisting of IL-10, IL-5, IL-8, PLGF, SICAM-1, sVCAM-1, IL-1, IL-2, IL-3, IL-4, IL-6, IL-9, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-20, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), vascular endothelial growth factor D (VEGF-D), macrophage inflammatory protein 1β (MIP-1β), leukemia inhibitory factor (LIF), oncostatin M (OSM), interferon (IFN) alpha, IFN-beta, IFN-gamma, tumor necrosis factor (TNF) alpha, TNF-beta, CD154, lymphotoxin (LT) beta, 4-1BB ligand (4-1BBL), a proliferation-inducing ligand (APRIL), CD70, CD153, CD178, glucocorticoid-induced TNFR-related ligand (GITRL), tumor necrosis factor superfamily member 14 (TNFSF14), OX40L, TNF-αnd ApoL-related leukocyte-expressed ligand 1 (TALL-1), TNF-related apoptosis-inducing ligand (TRAIL), chemokine (C-C motif) ligand (CCL) 1, macrophage inflammatory protein 1 alpha (MIP-1a or CCL3), CCL5, monocyte-specific chemokine 3 (MCP3 or CCL7), monocyte chemoattractant protein 2 (MCP-2 or CCL8), CCL13, thymus and activation regulated chemokine (TARC or CCL17), CCL22, and any combination thereof.
9 . The method of claim 1 , wherein a therapeutically effective amount of the engineered CAR T cells is about 1×10 6 cells/kg or 2×10 6 cells.
10 . The method of claim 1 , wherein the leukemia is acute lymphoblastic leukemia (ALL).
11 . The method of claim 1 , wherein the leukemia is selected from the group consisting of B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, hairy cell leukemia, Burkitt leukemia, T-cell prolymphocytic leukemia, T-cell large granular lymphocyte leukemia, aggressive NK cell leukemia, adult T-cell leukemia, B-lymphoblastic leukemia, B-lymphoblastic leukemia with recurrent genetic abnormalities, and T-lymphoblastic leukemia.
12 . The method of claim 1 , wherein the leukemia is a lymphoblastic leukemia.
Continuity (6)
Provisional Application
62262143
· Dec 2, 2015
Provisional Application
62167750
· May 28, 2015
References Cited (297)
US 5595756A
· Bally et al.
· 1997
[cited by applicant]
US 5728388A
· Terman
· 1998
[cited by applicant]
US 9855298B2
· Bot
· 2018
[cited by applicant]
US 20020006409A1
· Wood
· 2002
[cited by applicant]
US 20030031652A1
· Hering et al.
· 2003
[cited by applicant]
US 20130195800A1
· Roeth et al.
· 2013
[cited by applicant]
US 20140377334A1
· Irvine et al.
· 2014
[cited by applicant]
CL 2017003005A1
· 2018
[cited by applicant]
CL 2017003006A1
· 2018
[cited by applicant]
CN 104394877A
· 2015
[cited by applicant]
JP 2014507118A
· 2014
[cited by applicant]
JP 2014509841A
· 2014
[cited by applicant]
JP 6917903
· 2021
[cited by applicant]
KR 102349677B
· 2022
[cited by applicant]
OA 18685
· 2019
[cited by applicant]
WO 2004021995
· 2004
[cited by applicant]
WO WO2008081035A1
· 2008
[cited by applicant]
WO 2011119773A1
· 2011
[cited by applicant]
WO 2012079000A1
· 2012
[cited by applicant]
WO 2012099973A2
· 2012
[cited by applicant]
WO WO2013169386A1
· 2013
[cited by applicant]
WO WO2015069770A1
· 2015
[cited by applicant]
WO 2016191755A1
· 2016
[cited by applicant]
WO WO2016191756
· 2016
[cited by applicant]
WO WO2016191756A1
· 2016
[cited by applicant]
Office Action from counterpart Korean application Korean Patent Application No. 10 2022 7000444, dated Jul. 11, 2023 ( 3 pages).
[cited by applicant]
English translation of Office Action from counterpart Korean application Korean Patent Application No. 10 2022 7000444, dated Jul. 11, 2023 ( 6 pages).
[cited by applicant]
Examination report issued on Mar. 26, 2024 for counterpart NZ App. No. 776615 (4 pages).
[cited by applicant]
Examination report issued on Mar. 26, 2024 for counterpart NZ App. No. 776617 (3 pages).
[cited by applicant]
Office Action issued on Mar. 11, 2024 in related foreign but not counterpart Israel Application Serial No. 305621 (4 pages).
[cited by applicant]
Unfavourable Opinion issued Jan. 5, 2024 in related but not counterpart Brazilian application Nº BR122023022076-5 (8 pages).
[cited by applicant]
Notice of Allowance dated Aug. 21, 2023 in foreign related but not counterpart Israel Patent Application No. No. 284173 with English translation.
[cited by applicant]
IPO Search Report from foreign counterpart Taiwan Patent Application No. 111125144.
[cited by applicant]
Office Action issued Jun. 19, 2023 in foreign counterpart Taiwan Patent Application No. 111125144 with English translation.
[cited by applicant]
Office Action issued May 16, 2023 in foreign counterpart Brazilian Patent Application No. BR112017025166-3 with English translation.
[cited by applicant]
Office Action issued Jun. 19, 2023 in foreign counterpart Brazilian Patent Application No. BR122021025441-9with English translation.
[cited by applicant]
Foreign counterpart Japanese Patent Application No. 2021-110476, Decision to Grant and English translation, dated Jan. 23, 2023, 8 pages.
[cited by applicant]
Foreign counterpart Taiwan Patent Application No. 105116879, Allowance Decision of Re-Examination and English translation, dated Feb. 16, 2023, 3 pages.
[cited by applicant]
Office action issued May 16, 2023 in foreign counterpart Brazilian Patent Application Nº BR112017025166-3, Office, English translation attached.
[cited by applicant]
European Search Report with Opinion issued in related application EP 23157411.2 on Jul. 26, 2023 (10 pages).
[cited by applicant]
J. N. Kochenderfer et al: “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CDI9 chimeric-antigen-receptor-transduced T cells”, Blood, vol. 119, No. 12, D…
[cited by applicant]
Office Action issued Jul. 10, 2023 in related Brazil—Patent Application Nº BR112017025120-5 with English Translation.
[cited by applicant]
English Translation of Office Action issued Jul. 10, 2023 in related Brazil—Patent Application Nº BR112017025120-5.
[cited by applicant]
Office Action issued Jul. 11, 2023 in foreign Related Korean Patent Application No. 10-2022-7045189 with English translation.
[cited by applicant]
English Translation of Office Action issued Jul. 11, 2023 in foreign Related Korean Patent Application No. 10-2022-7045189 with English translation.
[cited by applicant]
Office Action issued Nov. 20, 2023 in related but not counterpart Brazilian application Nº BR112017025120-5 (10 pages).
[cited by applicant]
Statement of Opposition issued Nov. 22, 2023 in related but not counterpart European application No. 16800846.4 (58 pages).
[cited by applicant]
Proietti et al. (201 1) Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol Oncol. 6(1): 1-14, Dec. 3, 2011.
[cited by applicant]
Ding and Zhou (2012) Cytotoxic Chemotherapy and CD4+ Effector T Celis: An Emerging Alliance for Durable Antitumor Effects. Clin Dev Immunol. 890178, (12 pages) Nov. 5, 2011.
[cited by applicant]
Gattinoni et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumorspecific CD8+ T cells. J Exp Med. 202(7): 907-12, Oct. 3, 2005.
[cited by applicant]
Bot et al. (2015) Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to Car T Cell Therapy. Blood. 126(23): 4426, Dec. 7, 2015.
[cited by applicant]
NCT00924326 Study Record dated May 16, 2015. Available online at Record History I ver. 68: May 16, 2015 I NCT00924326 I ClinicalTrials.gov.
[cited by applicant]
Brentjens et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 1 18(18):4817-28.
[cited by applicant]
Porter et al. (2011) Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. N Engi J Med. 365(8): 725-33, Aug. 25, 2011.
[cited by applicant]
Dudley et al. (2008) Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. J Clin Oncol. 26(32): 5233-9.
[cited by applicant]
Moschella et al. (2013) Cyclophosphamide Induces a Type I Interferon-Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy. Clin Cancer Res. 19 (1…
[cited by applicant]
Rosenberg and Kochenderder (2011) Personalized Cell Transfer Immunotherapy for B-Cell Malignancies and Solid Cancers. Mol Ther. 19(11): 1928-1930.
[cited by applicant]
Kalos et al. (2011) T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sei Transl. Med. 3(95): 95ra73, Aug. 10, 2011.
[cited by applicant]
Supplementary Materials for T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sei Transl. Med. 3(95): 95ra73, Aug. 10, 2011.
[cited by applicant]
Examination report issued on Mar. 25, 2024 for counterpart EP App. No. 20204879.9 (5 pages).
[cited by applicant]
Related application but not foreign counterpart Vietnamese Patent Application No. 1-2017-05313: Office Action and English Translation Thereof dated Dec. 30, 2022, 4 pages.
[cited by applicant]
Office action issued Nov. 12, 2023 in foreign related but not counterpart Israel Patent Application Nº 284172, 4 pages.
[cited by applicant]
Office action issued Nov. 24, 2023 in foreign counterpart Taiwan Patent Application Nº 111125144, 11 pages.
[cited by applicant]
Office Action issued May 11, 2023 in related but not foreign counterpart Chinese Patent Office Action application No. 202210127095.8 with English translation.
[cited by applicant]
Clin. J. Clin. Obstet. Gynecol., vol. 14, No. 1,Jan. 31, 2013,Sun Xiaoling et al, “A case of hyponatremia due to chemotherapy”,p. 69, the right column the section Discussions, cited in related but not counterpart applic…
[cited by applicant]
Decision to Grant of related but not foreign counterpart Japanese Patent Application No. 2021-086807, May 30, 2023.
[cited by applicant]
Office Action issued Apr. 25, 2024 for counterpart Taiwan Application No. 111125144 (6 pages).
[cited by applicant]
Office Action issued Apr. 30, 2024 in related but not counterpart Canadian Patent Application No. 2,986,793 (4 pages).
[cited by applicant]
Office Action issued on May 8, 2024 in counterpart Saudi Application No. 521421432 (29).
[cited by applicant]
Office Action issued on Apr. 25, 2024 in related but not counterpart Saudi Application No. 521421433 (30).
[cited by applicant]
First Exam Report issued on May 15, 2024 in related but not Counterpart New Zealand patent application 737358.
[cited by applicant]
First Exam Report issued on May 15, 2024 in related but not Counterpart New Zealand patent application 776400.
[cited by applicant]
First Exam Report issued on May 15, 2024 in related but not Counterpart New Zealand patent application 776402.
[cited by applicant]
Office Action issued Jan. 8, 2024 in counterpart Israel Patent Application No. 295224 Jan. 8, 2024 (4 pages).
[cited by applicant]
Related application but not foreign counterpart Korean Patent Application No. 10-2022-7045189: Office Action and partial English Translation Thereof dated Feb. 27, 2023, 12 pages.
[cited by applicant]
Office Action issued Jan. 24, 2024 in foreign related Chinese application 02210019434.0 9 (14 pages).
[cited by applicant]
James N. Kochenderfer et al., Chemotherapy-Refractory Diffuse Large B-Cell Lymphomaand Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19Chimeric Antigen Receptor, ht…
[cited by applicant]
Jul. 1, 2024 Decision to Grant with English Translation for foreign related but not counterpart application in Japan—Patent Application Nº 2023-105613 (6 pages).
[cited by applicant]
Office Action issued Aug. 6, 2024 in foreign counterpart application Japanese Patent Application No. 2023-030596 (10 pages).
[cited by applicant]
Notice of Acceptance dated Aug. 7, 2024 in Foreign related but not corresponding NZ Application Serial No. 737358 (1 page).
[cited by applicant]
Further Examination Report issued Aug. 9, 2024 in Foreign corresponding New Zealand patent application 776615 (5 pages).
[cited by applicant]
Office action issued Oct. 6, 2023 in foreign counterpart Brazilian Patent Application Nº BR122021025400-1 Office, English translation attached.
[cited by applicant]
Final Office action issued Sep. 15, 2023 in foreign counterpart Brazilian Patent Application Nº BR112017025166-3, Office, English translation attached.
[cited by applicant]
Related application but not foreign counterpart Japanese Patent Application No. 2021-086807: Office Action and English Translation Thereof dated Dec. 13, 2022, 4 pages.
[cited by applicant]
Foreign counterpart Japanese Patent Application No. 2017-561794: Decision to Grant and English Translation Thereof dated Dec. 13, 2022, 4 pages.
[cited by applicant]
Office Action issued Jun. 6, 2023 in foreign related but not counterpart Vietnamese Patent Application No. 1-2023-02058 with English translation.
[cited by applicant]
Foreign counterpart Korean Patent Application No. 10-2022-7000444, Notice of Final Rejection and English translation, dated Mar. 3, 2023, 5 pages.
[cited by applicant]
Office Action issued Feb. 29, 2024 in foreign related but not counterpart Chinese application 202210127095.8 (12 pages).
[cited by applicant]
Office Action issued Feb. 19, 2024 in foreign related but not counterpart Brazilian application Nº BR122021025400-1 (8 pages).
[cited by applicant]
Notice of Allowance with English Translation of Allowed Claims for foreign counterpart application in Brazil—Patent Application Nº BR122021025400-1.
[cited by applicant]
Office Action issued Aug. 3, 2024 in foreign related but not counterpart Brazil application Serial No. Nº BR122024003420-4 ( 6 pages).
[cited by applicant]
Office Action issued Aug. 19, 2024 in foreign counterpart CN Application No. 202210019434.0 ( 10 pages) with English translation.
[cited by applicant]
Unfavourable opinion issued Aug. 13, 2024 in foreign related but not counterpart BR122023022076-5 (6 pages) with English translation.
[cited by applicant]
Unfavourable opinion issued Aug. 20, 2024 in foreign counterpart Brazilian Application No. BR122023017010-5 (14 pages) with English translation.
[cited by applicant]
Lee et al. “Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After…
[cited by applicant]
Melenhorst et al., “Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation”, Haematologica, vol. 97 No. 6, Jun. 2012, 867-873.
[cited by applicant]
Schultz and Arnold, “Properties of four acute phase proteins: C-reactive protein, serum amyloid a protein, α1-acid glycoprotein, and fibrinogen”, Seminars in Arthritis and Rheumatism, vol. 20, Issue 3, Dec. 1990, 129-14…
[cited by applicant]
PA-NPL1—Foreign Counterpart Korean Patent Application No. 10-2022-7000444: Office Action and English translation thereof, dated Oct. 13, 2022, 7 pages.
[cited by applicant]
PA-NPL2—Foreign Counterpart Mexican Patent Application No. MX/a/2017/015186: Office Action and English translation thereof, dated Oct. 21, 2022, 8 pages.
[cited by applicant]
PA-NPL3—Related But Not Foreign Counterpart Saudi Arabian Patent Application No. 521421433: Substantive Examination Report, and English translation thereof, dated Oct. 6, 2022, 8 pages.
[cited by applicant]
PA-NPL4—Foreign Counterpart Saudi Arabian Patent Application No. 521421432: Substantive Examination Report, and English translation thereof, dated Oct. 3, 2022, 8 pages.
[cited by applicant]
Bracci, L., et al., “Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor …
[cited by applicant]
Coiffier, B., et al., “CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma,”
[cited by applicant]
Dudley, M.E., et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,”
[cited by applicant]
Dudley, M.E., et al., “Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma,”
[cited by applicant]
Dudley, M.E., et al., “Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens,”
[cited by applicant]
Dudley, M.E., et al., “A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma,”
[cited by applicant]
Gattinoni, L., et al., “Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8
[cited by applicant]
Gisselbrecht, C., et al., “Salvage Regimens With Autologous Transplantation For Relapsed Large B-Cell Lymphoma in the Rituximab Era”
[cited by applicant]
Klebanoff, C.A., et al., “Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy,” Trends Immunol. 26(2):111-117, Elsevier Science Ltd., England (2005).
[cited by applicant]
Kochenderfer, J.N., et al., “B-Cell Depletion and Remissions of Malignancy Along with Cytokine-associated Toxicity in a Clinical Trial of Anti-CD19 Chimeric-Antigen-Receptor-Transduced T Cells,”
[cited by applicant]
Kochenderfer, J.N., et al., “Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor,”
[cited by applicant]
Kochenderfer, J.N., et al., “ Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma,”
[cited by applicant]
Moschella, F., et al., “Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy,”
[cited by applicant]
Moschella, F., et al., “Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide,”
[cited by applicant]
Rosenberg, S.A., et al., “Durable Complete Responses in Heavily Pretreated Patients With Metastatic Melanoma Using T-cell Transfer Immunotherapy,”
[cited by applicant]
Sehn, L.H., et al., “Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia”
[cited by applicant]
Turtle, C.J., et al., “CD19 CAR-T cells of defined CD4
[cited by applicant]
Ziccheddu, G., et al., “The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy,”
[cited by applicant]
Dehqanzada, Z.A., et al., “Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology,”
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/034885, ISA/US Commissioner for Patents, United States, mailed Sep. 8, 2016, 10 pages.
[cited by applicant]
Food and Drug Administration, “Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,” Jul. 2005, fda.gov, accessed at http://www.fda.go…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/34888, ISA/US Commissioner for Patents, United States, mailed Oct. 14, 2016, 14 pages.
[cited by applicant]
Guidance for Sponsors, Clinical Investigators, and IRBs Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials, Retrieved from the internet, URL: http://www.fda.gov/Drugs/default.htm published Oct. 200…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/34888, ISA/US, Commissioner for Patents, Alexandria, Virginia, mailed on Oct. 14, 2016, 14 pages.
[cited by applicant]
Khouri, I.F., et al., “Transplant-Lite: Induction of Graft-Versus-Malignancy Using Fludarabine-Based Nonablative Chemotherapy and Allogeneic Blood Progenitor-Cell Transplantation as Treatment for Lymphoid Malignancies,”…
[cited by applicant]
Maude, S.L., et al., “Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia,”
[cited by applicant]
O'Brien, S.M., et al., “Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia,” Journal of Clinical Oncology 19(5):1414-1420, American Society of Clinical Oncology, United S…
[cited by applicant]
Harrison, J., “Kite Reports Cerebral Edema Death in ZUMA-1 CAR T-Cell Trial,” Onclive.com, accessed at http://www.onclive.com/web-exclusives/kite-reports-cerebral-edema-death-in-zuma1-car-tcell-trial?p=1, accessed on Ju…
[cited by applicant]
Locke, F.L., et al., “Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma,” Mol Ther. 25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub Jan. 4, 20…
[cited by applicant]
Locke, F.L., et al., “Updated Phase 1 Results From ZUMA-1: A Phase 1-2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma,…
[cited by applicant]
Kochenderfer, J.N. et al., “Treatment of Chemotherapy-Refractory B-Cell Malignancies with Anti-CD19 Chimeric Antigen Receptor T cells,” Molecular Therapy May 21-24, 2014 Amer. Soc. Gene & Cell Therapy 22 (Suppl. 1): S29…
[cited by applicant]
Kochenderfer, J.N. and Rosenberg, S.A., “Treating B-cell cancer with T cells expressing anti-CD9 chimeric antigen receptors,” Nature Rev. Clin. Oncol. 10:267-276 (2013).
[cited by applicant]
Salit, R.B. et al., “Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies,” …
[cited by applicant]
Lee et al., “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trail,” Lancet, 385:571-528 (2015).
[cited by applicant]
Extended European Search Report for EP 16800847 dated Nov. 30, 2018. (8 pages).
[cited by applicant]
Office Action and English translation for counterpart Chilean application 201703006 dated Jan. 9, 2019 (17 pages).
[cited by applicant]
Written Opinion for Chilean Patent Application No. 201703006, which was issued on Jul. 4, 2019 and is related to this subject application (7 pages).
[cited by applicant]
English translation of the Written Opinion for Chilean Patent Application No. 201703006, which was issued on Jul. 4, 2019 and is related to this subject application (7 pages).
[cited by applicant]
Written Opinion for Chilean Patent Application No. 201703005, which was issued on Jul. 2, 2019 and is related to this subject application (7 pages).
[cited by applicant]
English translation of the Written Opinion for Chilean Patent Application No. 201703005, which was issued on Jul. 2, 2019 and is related to this subject application (7 pages).
[cited by applicant]
Office Action for U.S. Appl. No. 15/577,672, mailed Aug. 22, 2019, and is related to this corresponding application.
[cited by applicant]
Bracci et al., “Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infil…
[cited by applicant]
Park et al. “Impact of the Conditioning Chemotherapy on Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CDI 9-Targeted T Cells for Patients with Relapsed CLL”, Blood (2012), vol.…
[cited by applicant]
National Cancer Institute. “CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma” Available from: https://clinicaltrials.gov/ct2/show/NCT00924326. NLM identifier. NCT 00924326. First posted Jun. (Year: 20…
[cited by applicant]
Jain, RK., “Barriers to drug delivery in solid tumors”, Scientific American, Jul. 1994, vol. 271, pp. 58-65.
[cited by applicant]
Office Action Received for Taiwanese Patent Application Serial No. TW105116879, dated Jan. 15, 2020, 13 pages.
[cited by applicant]
Hong et al., “Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy”, Clinical Cancer Research, 2010, vol. 16, No. 19, pp. 4892-4898.
[cited by applicant]
Preliminary Examination Report received for Singaporean Patent Application Serial No. 10201913604T dated Feb. 10, 2020, 1 page.
[cited by applicant]
Preliminary Examination Report received for Singaporean Patent Application Serial No. 10201913623P dated Mar. 3, 2020, 2 pages.
[cited by applicant]
Preliminary Examination Report received for Singaporean Patent Application Serial No. 10201913613S dated Mar. 3, 2020, 2 pages.
[cited by applicant]
Original and English Translation of Office Action issued in related (not counterpart) Eurasian Patent Application No. 201792642/28 mailed on Mar. 17, 2020.
[cited by applicant]
Preliminary Examination Report mailed Mar. 3, 2020 in in related (not counterpart) Singapore Patent Application No. 10201913620Q.
[cited by applicant]
Examination report issued Apr. 3, 2020 in in related (not counterpart) European Patent application No. 16800846.4.
[cited by applicant]
Rosenberg et al., “Personalized Cell Transfer Immunotherapy for B-Cell Malignancies and Solid Cancers,” Molecular Therapy, Nov. 2011, vol. 19, No. 11, pp. 1928-1931.
[cited by applicant]
Huang et al., “Synergistic effect of adoptive T-cell therapy and intratumoral interferon y-inducible protein—10 transgene expression in treatment of established tumors,” Cellular Immunology, 2002, vol. 271, pp. 12-22.
[cited by applicant]
Bot et al., “Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CART Cell Therapy,” Blood, 2015, vol. 126, pp. 4426.
[cited by applicant]
Perez et al., “Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy,” Blood, 126:2042 (2015).
[cited by applicant]
Rossi et al., “Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CART Cells (KTE-C19) in Subjects with Refractory Aggressive Non…
[cited by applicant]
Chilean Office Action for Application No. 201703005 dated Jan. 8, 2019, 13 pages (Including English Translation).
[cited by applicant]
Extended European Search Report for EP 16800846 dated Dec. 12, 2018 (19 pages).
[cited by applicant]
EPO Communication pursuant to Rules 70(2) and 70a(2) EPC for EP Application No. 16800847.2 dated Dec. 18, 2018, which is related to this subject application.
[cited by applicant]
Official Action for Eurasian Application No. 2001792649 dated May 6, 2019, which is related to this subject application.
[cited by applicant]
English Translation of Official Action for Eurasian Application No. 2001792649 dated May 6, 2019, which is related to his subject application.
[cited by applicant]
EPO Communication pursuant to Rules 70(2) and 70a(2) EPC for EP Application No. 16800846.4 dated Jan. 8, 2019 which is related to this subject application.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/649,369, dated Feb. 14, 2019, which is related to this application.
[cited by applicant]
Final Office Action for U.S. Appl. No. 15/649,369, dated Nov. 5, 2018, which is related to this application.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/649,369, dated Jul. 13, 2018, which is related to this application.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/649,369, dated Oct. 19, 2017, which is related to this application.
[cited by applicant]
Notice to File Corrected Application Papers for U.S. Appl. No. 15/649,369, dated Jul. 20, 2017, which is related to this application.
[cited by applicant]
Notice of Abandonment for U.S. Appl. No. 15/295,931, dated Jul. 5, 2017, which is related to this application.
[cited by applicant]
Notice to File Missing Parts for U.S. Appl. No. 15/295,931, dated Oct. 31, 2016, which is related to this application.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/167,977, dated Jul. 28, 2017, which is related to this application.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/167,977, dated Jul. 14, 2017, which is related to this application.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/167,977, dated Feb. 6, 2017, which is related to this application.
[cited by applicant]
Notice of Omitted Items for U.S. Appl. No. 15/167,977, dated Jun. 14, 2016, which is related to this application.
[cited by applicant]
Communication pursuant to Article 94(3) EPC received for European Patent Application Serial No. 16800847.2 dated Apr. 28, 2020, 4 pages,.
[cited by applicant]
International Preliminary Report on Patentability Chapter I received for PCT Application Serial No. PCT/US2016/034888 dated Dec. 7, 2017, 11 pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC received for European Patent Application Serial No. 16800846.4 dated Apr. 3, 2020, 4 pages.
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2017561968 dated May 12, 2020, 6 pages (Including English Translation).
[cited by applicant]
Final Office Action received for U.S. Appl. No. 15/577,672 dated Feb. 21, 2020, 39 pages.
[cited by applicant]
Original and English Translation of Office Action mailed Mar. 19, 2020 in counterpart Indonesian Patent Application No. P00201709434.
[cited by applicant]
Original and English Translation of Office Action mailed Jun. 23, 2020 in counterpart Japanese Patent Application No. 2017-561794.
[cited by applicant]
English Translation and Original Examination Report issued on Jul. 14, 2020 in Saudi Arabian Patent Application No. 517390394, foreign counterpart.
[cited by applicant]
English Translation and Original Examination Report issued on Jul. 8, 2020 in Saudi Arabian Patent Application No. 517390396, related subject matter.
[cited by applicant]
English Translation and Original Office Action issued on Jun. 23, 2020 in Japanese Patent Application No. 2017-561794, foreign counterpart.
[cited by applicant]
Original and English Translation of Office Action mailed Aug. 5, 2020 in Taiwan Patent Application No. 105116879, counterpart application.
[cited by applicant]
Office Action dated Sep. 2, 2020 for Chinese Patent Application No. 201680030892.7.
[cited by applicant]
Office Action dated Oct. 10, 2020 for Chinese Patent Application No. 201680038203.7.
[cited by applicant]
Guifang, Li, “An excerpt of results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia,” Foreign Medical Sciences (Cancer Section), 29(2), 158-159.
[cited by applicant]
O'Brien S M, et al. (2001), “Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia,” J Clin Oncol, 19(5), 1414-20.
[cited by applicant]
Yadan, L. et al. (2015), CD19 and immunotherapy of B-cell lineage malignancies, Chin J Cancer Biother, 22(1), 99-103.
[cited by applicant]
Office Action dated Nov. 4, 2020 for Israel Patent Application No. 255888.
[cited by applicant]
Office Action dated Nov. 2, 2020 for Israel Patent Application No. 255887.
[cited by applicant]
Jie et al. (2014), “Introduction of Chimeric Antigen Receptor-engineered T Cells and the Clinical Use for Anticancer,” 36(2), 1-8.
[cited by applicant]
Office Action dated Dec. 8, 2020 for counterpart Saudi Arabia Application No. 517390394, English translation and original version.
[cited by applicant]
Office Action dated Dec. 10, 202 for Saudi Arabia Patent Application No. 517390396, English translation and original version.
[cited by applicant]
Oflice Action dated Jan. 26, 2021 for Japanese Patent Application No. 2017-561968, English translation and original version.
[cited by applicant]
Oflice Action dated Mar. 2, 2021 for counterpart Japanese Patent Application No. 2017-561794, English translation and original version.
[cited by applicant]
Examination Report No. 1 in counterpart Australian Application No. 2016268864, dated May 18, 2021.
[cited by applicant]
Second Office Action in counterpart Chinese Application No. 201680030892.7, dated May 26, 2021.
[cited by applicant]
English translation of Second Office Action in counterpart Chinese Application No. 201680030892.7, dated May 26, 2021.
[cited by applicant]
Second Office Action in related Chinese Application No. 201680038203.7, dated Jun. 7, 2021.
[cited by applicant]
English translation of Second Office Action in related Chinese Application No. 201680038203.7, dated Jun. 7, 2021.
[cited by applicant]
Examination Report issued in related European Patent Application No. 16800846.4, mailed Jun. 23, 2021, 9 pages.
[cited by applicant]
Patent Examination Report 1 issued in New Zealand Patent Application No. 737359, mailed Jun. 21, 2021, 4 pages.
[cited by applicant]
Notice of Preliminary Rejection and its English translation issued in Korean Patent Application No. 10-2017-7037017, mailed Aug. 8, 2021, 5 pages.
[cited by applicant]
Third Party Observations submitted in related EP Application No. 16800846.4 with the European Patent Office on Jan. 25, 2021, 5 pages.
[cited by applicant]
Office Action and English translation issued in related Chinese Patent Application No. 201680038203.7, mailed Jun. 7, 2021, 28 pages.
[cited by applicant]
Rejection Notification and English translation issued in related Saudi Arabian Patent Application No. 517390396, issued Jun. 30, 2021, 8 pages.
[cited by applicant]
Decision to Grant a Patent and English Translation issued in Japanese Patent Application No. 2017-561968, mailed Jun. 29, 2021, 6 pages.
[cited by applicant]
Examination Report No. 1 issued in Australian Patent Application No. 2016268863, mailed Jun. 15, 2021, 6 pages.
[cited by applicant]
Substantive Examination Report (Restriction) issued in Philippine Patent Application No. 1/2017/502154, mailed Marcy 2, 2021, 4 pages.
[cited by applicant]
Extended European Search Reportissued in European Patent Application No. 20204879.9, mailed Jun. 17, 2021, 8 pages.
[cited by applicant]
Clarification—Preliminary Examination issued in SG Patent Application No. 10201913613S, mailed Mar. 3, 2020, 2 pages.
[cited by applicant]
Brentjens, R. et al. “Treatment of Chronic Lymphocytic Leukemia with Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial,” The American Society of Gene & Cell …
[cited by applicant]
Kalos, M., et al. “T Cells with Chimeric Antigen Receptors Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukaemia,” Presentation by Thressi Maxwell, Neurochemistry Laboratory CMC, Sep. 201…
[cited by applicant]
ClinicalTrials.gov, “CAR T Receptor Immunotherapy for Patients with B-Cell Lymphoma,” National Cancer Institute, Clinical Trial Identifier No. NCT00924326, results posted: Mar. 21, 2019, 23 pages.
[cited by applicant]
Office Action issued in counterpart Brazilian application BR112017025166-3 on Sep. 14, 2021, and English Translation of the same.
[cited by applicant]
Original and English Translation of Rejection Decision mailed Oct. 20, 2021, in Chinese Patent Application No. 201680030892.7.
[cited by applicant]
Original and English Translation of Substantive Examination mailed Oct. 11, 2021, in Mexican Patent Application No. MX/a/2017/015186.
[cited by applicant]
Original and English Translation of Substantive Office Action mailed Oct. 22, 2021, in Vietnamese Patent Application No. 1-2017-05303.
[cited by applicant]
Original and English Translation of Preliminary Rejection mailed Dec. 21, 2021, in Korean Patent Application No. 10-2017-7037018.
[cited by applicant]
English language Patent Examination Report mailed Jan. 10, 2022 in New Zealand Patent Application No. 737359.
[cited by applicant]
Original and English Translation of Rejection Decision mailed Nov. 1, 2021, in Chinese Patent Application No. 201680038203.7.
[cited by applicant]
Original and English Translation of Substantive Office Action mailed Oct. 22, 2021, in Vietnamese Patent Application No. 1-2017-05313.
[cited by applicant]
Pawel Muranski et al., “Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?”, Nature Clinical Practice Oncology, vol. 3 (No. 12):pp. 668-681 (Dec. 2006).
[cited by applicant]
Taiwan Office Action issued Jan. 6, 2022 in connection with Taiwan Application No. 105116879, 10 pages.
[cited by applicant]
English language translation of Taiwan Office Action issued Jan. 6, 2022 in connection with Taiwan Application No. 105116879, 13 pages.
[cited by applicant]
Taiwan Search Report issued Jan. 6, 2022 in connection with Taiwan Application No. 105116879, 1 page.
[cited by applicant]
Australian Examination Report dated Mar. 29, 2022 in connection with co-pending Australian Application No. 2016268863, 3 pages (all references cited in this Office Action have been previously submitted in earlier IDSs).
[cited by applicant]
Canadian Office Action issued Jul. 4, 2022 in connection with Canadian Application No. 2,986,793, which has related subject matter but is not foreign counterpart, 7 pages.
[cited by applicant]
European Communication issued Sep. 16, 2022 in connection with European Application No. 16800846.4. which has related subject matter but is not foreign counterpart, 7 pages.
[cited by applicant]
New Zealand Office Action issued Jul. 13, 2022 in connection with New Zealand Application No. 737359, 5 pages.
[cited by applicant]
Japanese Office Action, with English translation, issued Jul. 26, 2022 in connection with Japanese Application No. 2017-561794, 10 pages.
[cited by applicant]
Taiwan Office Action issued Sep. 13, 2022 in connection with Taiwan Application No. 105116879, 4 pages.
[cited by applicant]
English translation of Taiwan Office Action issued Sep. 13, 2022 in connection with Taiwan Application No. 105116879, 4 pages.
[cited by applicant]
Lee et al. (Blood 2012, 120: Ab. No. 2609) (Year: 2012).
[cited by applicant]
Schultz and Amold (Seminars in Arthritis and Rheumatism Dec. 1990) (Year: 1990).
[cited by applicant]
Melenhorst et al. (Haematologica 2012: 97(6): 867-873) (Year: 2012).
[cited by applicant]
Dudley et al. (J. Clinical Oncology Nov. 10, 2008 26 (32): 5233-5239) (Year: 2008).
[cited by applicant]
Office action issued Dec. 20, 2023 in foreign related but not counterpart CN Appln.202210127095.8, 14pages.
[cited by applicant]
Office action issued Dec. 11, 2023 in foreign related but not counterpart SA Div. Pat. App. 521421433, 13 pages.
[cited by applicant]
Office action issued Dec. 11, 2023 in foreign counterpart SA Pat. App. 521421432, 10 pages.
[cited by applicant]
Preliminary Rejection issued on Nov. 26, 2024 in related but not counterpart Foreign Application KR Patent Application No. 10-2023-7034799 with English translation. (8 pages).
[cited by applicant]
Notice of Allowance issued Jul. 30, 2024 in Foreign Related but not Corresponding Israel Patent Application No. 284172 (3 pages).
[cited by applicant]
Office Action issued Sep. 18, 2024 in Foreign Corresponding Australian Application Serial No. 2022224754 (6 pages).
[cited by applicant]
Notice of Allowance issued Sep. 24, 2024 in Foreign Corresponding Taiwan Patent Application No. 111125144 with English translation ( 3 pages).
[cited by applicant]
Rejection opinion issued on Dec. 9, 2024 for Foreign counterpart Brazil Application No. BR122023017010-5 with English Translation (13 pages).
[cited by applicant]
Further Examination Report issued Nov. 26, 2024 counterpart NZ Application 776615. (6 pages).
[cited by applicant]
Office Action issued Dec. 13, 2024 in foreign related but not counterpart Brazil Application No. BR122024003420-4 with English translation (8 pages).
[cited by applicant]
Examination report issued Dec. 16, 2024 in foreign related but not counterpart Australian patent application 2022231653 (5 pages).
[cited by applicant]
Preliminary Rejection issued on Oct. 28, 2024 in counterpart foreign KR Appln. No. 10-2023-7034999 with English translation. (8 pages).
[cited by applicant]
Office Action issued Oct. 31, 2024 in counterpart foreign VN Patent Application No. 1-2022-00407 with English translation. (4 pages).
[cited by applicant]
Examination Report issued on Nov. 1, 2024 in related but not counterpart Foreign Application NZ Patent Application No. 737358. (3 pages).
[cited by applicant]
Office Action issued Dec. 3, 2024 in Foreign counterpart Canadian Application 2,986,798 (9 pages).
[cited by applicant]
Final Rejection issued Jan. 13, 2025 in foreign counterpart Chinese Application No. 202210019434.0, with English translation (9 pages).
[cited by applicant]
Notice of Allowance issued Jan. 28, 2025 to foreign counterpart Israeli Application No. 295224 (3 pages).
[cited by applicant]
Decision of Final Rejection mailed Mar. 5, 2025 in foreign Counterpart Japanese Patent Application 2023-030596 with English translation (6 pages).
[cited by applicant]
Notice of Application in Order of for Acceptance issued on Mar. 6, 2025 for foreign related but not counterpart New Zealand patent application 737358. (Two pages).
[cited by applicant]
Examination Report issued Jan. 14, 2025 in related foreign but not counterpart European Application No. EP 23157411.2 (7 pages).
[cited by applicant]
Rejection issued Jan. 14, 2025 in related foreign but not counterpart Brazilian Application No. BR122023022076-5, (6 pages).
[cited by applicant]
Second Examination Report issued Mar. 4, 2025 in related but not Counterpart New Zealand Application No. 776400 (7 pages).
[cited by applicant]
Carpenter, Robert O., et al, “B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma”, Clin Cancer Res, vol. 19, No. 8, pp. 2048-2060, Jan. 23, 2013.
[cited by applicant]
Rosenberg, Steven A., “Adoptive cell transfer as personalized immunotherapy for human cancer”, Science, vol. 348, No. 6230, pp. 62-68, Apr. 3, 2015.
[cited by applicant]
Office Action issued Jan. 22, 2025 in related but not Counterpart Israel Patent Application No. 316196 (4 pages).
[cited by applicant]
Office Action issued Apr. 23, 2025 in Foreign Counterpart Application No. 112135845 in Taiwan with English translation. (11 pages).
[cited by applicant]
Second Examination Report issued Apr. 30, 2025 in Foreign Counterpart Australian Application No. 2022224754 (4 pages).
[cited by applicant]
Fifth Examination Report issued May 1, 2025 in Foreign Counterpart New Zealand Application No. 776615 (10 pages).
[cited by applicant]
Office Action issued May 21, 2025 in related U.S. Appl. No. 18/455,033 (21 pages).
[cited by applicant]
Second Examination Report Issued Mar. 4, 2025 in Foreign Related but not Counterpart New Zealand Application No. 776402 (7 pages).
[cited by applicant]
Gilham, David E. et al. , ‘CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe’, Trends in Molecular Medicine, vol. 18, No. 7, pp. 377-384.
[cited by applicant]
Lamers, C.H. et al., ‘Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.’, Molecular therapy, vol. 21, No. 4, pp. 904-912.
[cited by applicant]
Final Rejection Issued Jun. 9, 2025 in Foreign Counterpart Korean Application No. 10-2023-7034999 with English translation. (9 pages).
[cited by applicant]
Third Examination Report Issued May 30, 2025 in Foreign Related but not Counterpart New Zealand Application No. 776400 (6 pages).
[cited by applicant]
Gill, S. and June, C.H., ‘Going viral: chimeric antigen receptor Tcell therapy for hematological malignancies’, Immunological Reviews, vol. 263, No. 1, pp. 68-89.
[cited by applicant]
Notice of Acceptance Issued Jul. 16, 2025 in Foreign Related but not Counterpart New Zealand Application No. 776400 (2 pages).
[cited by applicant]
Notice of Acceptance Issued Jul. 16, 2025 in Foreign Related but not Counterpart New Zealand Application No. 776402 (2 pages).
[cited by applicant]
Third Examination Report Issued Jul. 16, 2025 in Foreign Related but not Counterpart New Zealand Application No. 776402 (1 pages).
[cited by applicant]
Fourth Examination Report Issued Jul. 16, 2025 in Foreign Related but not Counterpart New Zealand Application No. 776400 (1 pages).
[cited by applicant]
Third Examination Report issued Jul. 10, 2025 in Foreign Counterpart Australian Application No. 2022224754 (2 pages).
[cited by applicant]